DOP2020000107A - Composiciones inmunoestimulantes - Google Patents

Composiciones inmunoestimulantes

Info

Publication number
DOP2020000107A
DOP2020000107A DO2020000107A DO2020000107A DOP2020000107A DO P2020000107 A DOP2020000107 A DO P2020000107A DO 2020000107 A DO2020000107 A DO 2020000107A DO 2020000107 A DO2020000107 A DO 2020000107A DO P2020000107 A DOP2020000107 A DO P2020000107A
Authority
DO
Dominican Republic
Prior art keywords
compositions
immunestimulant
immunostimulating
toll
stimulate
Prior art date
Application number
DO2020000107A
Other languages
English (en)
Inventor
Ilg Thomas
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of DOP2020000107A publication Critical patent/DOP2020000107A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción se refiere a composiciones inmunoestimulantes que son eficaces para provocar respuestas inmunitarias en especies de aves. Más específicamente, estas composiciones inmunoestimulantes comprenden una composición inmunomoduladora y un oligonucleótido inmunoestimulante que, al administrarse, estimulan el receptor tipo toll 21.
DO2020000107A 2017-12-15 2020-06-10 Composiciones inmunoestimulantes DOP2020000107A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17207740 2017-12-15
EP17207746 2017-12-15
EP17207750 2017-12-15
PCT/EP2018/083956 WO2019115385A1 (en) 2017-12-15 2018-12-07 Immunostimulatory compositions

Publications (1)

Publication Number Publication Date
DOP2020000107A true DOP2020000107A (es) 2020-08-31

Family

ID=66818991

Family Applications (3)

Application Number Title Priority Date Filing Date
DO2020000106A DOP2020000106A (es) 2017-12-15 2020-06-10 Oligonucleótidos inmunoestimulantes
DO2020000107A DOP2020000107A (es) 2017-12-15 2020-06-10 Composiciones inmunoestimulantes
DO2020000113A DOP2020000113A (es) 2017-12-15 2020-06-10 Oligonucleótidos inmunoestimulantes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DO2020000106A DOP2020000106A (es) 2017-12-15 2020-06-10 Oligonucleótidos inmunoestimulantes

Family Applications After (1)

Application Number Title Priority Date Filing Date
DO2020000113A DOP2020000113A (es) 2017-12-15 2020-06-10 Oligonucleótidos inmunoestimulantes

Country Status (21)

Country Link
US (6) US11932857B2 (es)
EP (3) EP3701032A1 (es)
JP (5) JP7273040B2 (es)
KR (3) KR20200098638A (es)
CN (3) CN111447949A (es)
AU (3) AU2018385257A1 (es)
BR (3) BR112020011845A2 (es)
CA (3) CA3085657A1 (es)
CL (3) CL2020001562A1 (es)
CO (3) CO2020007100A2 (es)
CR (1) CR20200260A (es)
DO (3) DOP2020000106A (es)
IL (3) IL274975A (es)
MX (3) MX2020006243A (es)
PE (2) PE20210636A1 (es)
PH (3) PH12020550906A1 (es)
SG (3) SG11202004471RA (es)
TW (3) TWI821224B (es)
UY (3) UY38016A (es)
WO (3) WO2019115386A1 (es)
ZA (1) ZA202004317B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022538690A (ja) 2019-07-05 2022-09-05 タンボ・インコーポレイテッド トランス－シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用
CN113493790A (zh) * 2020-04-01 2021-10-12 南京华普生物技术股份有限公司 具有免疫调节功能的CpG ODN及其应用
CN116056765A (zh) 2020-08-07 2023-05-02 坦伯公司 反式环辛烯生物正交剂及在癌症和免疫疗法中的用途
CN112159814B (zh) * 2020-10-29 2023-05-16 中国农业科学院兰州兽医研究所 一种CpG寡聚脱氧核苷酸及制备与其用途
CN113797329A (zh) * 2021-10-19 2021-12-17 启锰生物科技(江苏)有限公司 一种二价锰佐剂和CpG佐剂的疫苗佐剂组合物及其制作方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719028A (en) * 1992-12-07 1998-02-17 Third Wave Technologies Inc. Cleavase fragment length polymorphism
US6194388B1 (en) 1994-07-15 2001-02-27 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
EE200200158A (et) * 1999-09-25 2003-06-16 University Of Iowa Research Foundation Immunostimulatoorsed nukleiinhapped
MXPA02003059A (es) * 1999-09-27 2002-09-30 Univ Iowa Res Found Metodos relacionados con interferon inducido por acido nucleico inmunoestabilizador.
KR100359753B1 (ko) * 1999-12-21 2002-11-09 주식회사 제넥신 면역조절능력 및 안전성이 증가되고 ｄＧ 연속서열이결합된 포스포다이에스터 ＣｐＧ올리고데옥시뉴클레오티드 변형체
AR040996A1 (es) * 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
CA2528597C (en) * 2003-06-11 2014-08-05 Hybridon, Inc. Stabilized immunomodulatory oligonucleotides
JP4989225B2 (ja) 2003-09-25 2012-08-01 コーリー ファーマシューティカル グループ，インコーポレイテッド 核酸親油性接合体
OA13278A (en) * 2003-10-30 2007-01-31 Coley Pharm Gmbh C-Class oligonucleotide analogs with enhanced immunostimulatory potency.
CA2543072A1 (en) * 2003-11-05 2005-06-02 Pevion Biotech Ltd. Compositions comprising melittin-derived peptides and methods for the potentiation of immune responses against target antigens
KR100558851B1 (ko) 2004-01-08 2006-03-10 학교법인연세대학교 면역조절능력이 증가된 ＣｐＧ 올리고데옥시뉴클레오티드변형체
AU2005247341B2 (en) * 2004-05-06 2008-05-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods and compositions for the treatment of uveitis
JP2008531018A (ja) * 2005-02-24 2008-08-14 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫刺激性オリゴヌクレオチド
EP1764108A1 (en) * 2005-09-14 2007-03-21 Gunther Hartmann Compositions comprising immunostimulatory RNA oligonucleotides and methods for producing said RNA oligonucleotides
CA2642152C (en) 2006-02-15 2016-11-01 Coley Pharmaceutical Gmbh Compositions and methods for oligonucleotide formulations
CN100418583C (zh) * 2006-02-21 2008-09-17 朱鸿飞 预防和治疗乳腺炎的药物组合物
US20080124366A1 (en) 2006-08-06 2008-05-29 Ohlfest John R Methods and Compositions for Treating Tumors
CN102851295B (zh) * 2006-08-28 2015-01-07 长春华普生物技术有限公司 Toll 样受体调节性寡核苷酸及其用途
NZ575437A (en) 2006-09-27 2012-02-24 Coley Pharm Gmbh Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
TR201820474T4 (tr) * 2007-08-13 2019-01-21 Zoetis Belgium S A Spesifik immün modülatör profilleri indükleyen tanımlı nükleotitler arası bağlar bağlamında rna sekansı motifleri.
EP2427472B1 (en) 2009-05-05 2016-06-22 Miragen Therapeutics Lipophilic polynucleotide conjugates
EP2429581B1 (en) 2009-05-14 2015-08-05 Bayer Intellectual Property GmbH Enhanced immune response in avian species
BR112012030337B1 (pt) * 2010-05-28 2021-04-27 Coley Pharmaceutical Group, Inc Vacina compreendendo um ou mais oligonucleotídeo(s) de cpg isolado(s) ou um agonista de tlr e colesterol, e uso da mesma
RU2606855C2 (ru) 2010-12-22 2017-01-10 Байер Интеллектчуал Проперти Гмбх Повышение иммунного отклика у видов крупного рогатого скота
EP2471926A3 (en) * 2010-12-30 2012-07-11 Intervet International BV Immunostimulatory oligodeoxynucleotides
CA2834440A1 (en) * 2011-05-26 2012-11-29 Intervet International B.V. Immunostimulatory oligodeoxynucleotides
BR112013029968A2 (pt) * 2011-05-26 2017-01-31 Intervet Int Bv oligodesoxinucleotídeo imunoestimulatório não metilado, vetor, vacina para prevenir ou combater uma doença infecciosa, e, método para a detecção de oligodesoxinucleotídeos imunoestimulatórios
JP6375289B2 (ja) 2012-04-05 2018-08-15 マサチューセッツ インスティテュート オブ テクノロジー 免疫刺激組成物およびその使用方法
AR091569A1 (es) * 2012-06-28 2015-02-11 Intervet Int Bv Receptores de tipo toll
AU2013347838A1 (en) * 2012-11-26 2015-06-11 Caris Life Sciences Switzerland Holdings Gmbh Biomarker compositions and methods
AU2014259953B2 (en) * 2013-05-01 2020-07-02 Regulus Therapeutics Inc. Compounds and methods for enhanced cellular uptake
TWI535451B (zh) * 2013-07-19 2016-06-01 財團法人國家衛生研究院 CpG寡去氧核苷酸、包含其之免疫組合物及組合物用於製備治療以刺激免疫反應的藥物之用途
AR097029A1 (es) * 2013-07-26 2016-02-17 Intervet Int Bv Aceleración de la respuesta inmune inducida por virus vectorial en aves, composición, uso, método para la vacunación y método para acelerar la respuesta inmune
GB2517700A (en) * 2013-08-27 2015-03-04 Lgc Ltd Oligonucleotides comprising a secondary structure and uses thereof
KR20160122849A (ko) 2014-02-28 2016-10-24 바이엘 애니멀 헬스 게엠베하 면역자극성 플라스미드
WO2017139570A1 (en) * 2016-02-12 2017-08-17 Massachusetts Intitute Of Technology Synergistic tumor treatment with il-2, an integrin-binding-fc fusion protein, and a cancer vaccinne

Also Published As

Publication number Publication date
EP3701032A1 (en) 2020-09-02
IL274975A (en) 2020-07-30
CL2020001562A1 (es) 2020-11-06
EP3700564A1 (en) 2020-09-02
CN111801419A (zh) 2020-10-20
US20230174990A1 (en) 2023-06-08
CA3085661A1 (en) 2019-06-20
CO2020007102A2 (es) 2020-06-19
PH12020550906A1 (en) 2021-05-17
CO2020007100A2 (es) 2020-06-19
DOP2020000106A (es) 2020-08-31
TW201940192A (zh) 2019-10-16
US20210062192A1 (en) 2021-03-04
US20210170020A1 (en) 2021-06-10
PE20210635A1 (es) 2021-03-23
US11542507B2 (en) 2023-01-03
TW201936923A (zh) 2019-09-16
CR20200260A (es) 2020-08-01
US11932857B2 (en) 2024-03-19
CA3085575A1 (en) 2019-06-20
MX2020006244A (es) 2020-09-03
JP2021506779A (ja) 2021-02-22
UY38015A (es) 2019-06-28
UY38014A (es) 2019-06-28
JP2023153970A (ja) 2023-10-18
SG11202004952UA (en) 2020-06-29
RU2020122545A (ru) 2022-01-19
MX2020006243A (es) 2020-09-03
WO2019115386A1 (en) 2019-06-20
CA3085657A1 (en) 2019-06-20
PE20210636A1 (es) 2021-03-23
EP3694549A1 (en) 2020-08-19
CL2020001560A1 (es) 2020-11-06
KR20200098637A (ko) 2020-08-20
WO2019115402A1 (en) 2019-06-20
RU2020122545A3 (es) 2022-05-04
CO2020007120A2 (es) 2020-06-19
TW201936924A (zh) 2019-09-16
AU2018382419A1 (en) 2020-06-04
JP7458977B2 (ja) 2024-04-01
WO2019115386A9 (en) 2020-07-23
US20230332162A1 (en) 2023-10-19
TWI821224B (zh) 2023-11-11
MX2020006246A (es) 2020-09-03
JP2021506245A (ja) 2021-02-22
JP2021506246A (ja) 2021-02-22
US20200385733A1 (en) 2020-12-10
JP7273040B2 (ja) 2023-05-12
PH12020550904A1 (en) 2021-05-17
CN111447949A (zh) 2020-07-24
CL2020001561A1 (es) 2020-11-06
RU2020122553A (ru) 2022-01-17
BR112020011838A2 (pt) 2020-11-24
US20240076681A1 (en) 2024-03-07
CN111801116A (zh) 2020-10-20
SG11202004471RA (en) 2020-06-29
AU2018385256A1 (en) 2020-06-11
KR20200099556A (ko) 2020-08-24
BR112020011815A2 (pt) 2020-11-17
DOP2020000113A (es) 2020-08-31
JP2023156485A (ja) 2023-10-24
IL275086A (en) 2020-07-30
IL275217A (en) 2020-07-30
PH12020550903A1 (en) 2021-05-17
WO2019115385A1 (en) 2019-06-20
AU2018385257A1 (en) 2020-06-18
BR112020011845A2 (pt) 2020-11-24
UY38016A (es) 2019-06-28
ZA202004317B (en) 2023-05-31
KR20200098638A (ko) 2020-08-20
SG11202004773SA (en) 2020-06-29

Similar Documents

Publication Publication Date Title
DOP2020000107A (es) Composiciones inmunoestimulantes
IL282215A (en) Immunogenic preparations that include conjugated capsular saccharide antigens and their uses
ZA201903620B (en) Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
WO2016019134A8 (en) Flagellin-based agents and uses including effective vaccination
CR20160393A (es) Plásmidos inmunoestimuladores
MY194449A (en) Zika vaccines and immunogenic compositions, and methods of using the same
PH12017500117A1 (en) Use of visual clues to enhance bird repellent compositions
WO2016179034A3 (en) Methods and compositions for stimulating immune response using potent immunostimulatory rna motifs
MX2021015972A (es) Vacuna contra la fiebre aftosa.
CU20160193A7 (es) Composiciones y métodos para mejorar la inmunidad
AR097029A1 (es) Aceleración de la respuesta inmune inducida por virus vectorial en aves, composición, uso, método para la vacunación y método para acelerar la respuesta inmune
AR113950A1 (es) Composiciones inmunoestimulantes
AR113949A1 (es) Oligonucleótidos inmunoestimulantes
SG11202106494RA (en) Compositions, methods and uses for eliciting an immune response
DOP2019000018A (es) Aumento de la fertilidad en especies bovinas
AR105539A1 (es) Potenciamiento de la respuesta inmunológica en especies acuáticas
CR20200261A (es) Oligonucleótidos inmunoestimulantes
EP4175653A4 (en) COMPOSITIONS WITH NATURAL EXTRACTS TO STIMULATE THE IMMUNE RESPONSE
LT3534891T (lt) Geriamoji kompozicija su imunomoduluojančiu poveikiu nk ląstelėms